Drug Type Small molecule drug |
Synonyms |
Action antagonists |
Mechanism 5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H26Cl2FN3O |
InChIKeyHEMQRYHBBROCGT-ZMBIFBSDSA-N |
CAS Registry172732-21-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Preclinical | Japan | 08 Oct 1997 | |
Psychotic Disorders | Preclinical | Japan | - | - |